Jane Street’s Viridian Therapeutics VRDN Stock Holding History

Jane Street’s Portfolio VRDN Stock Details VRDN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$551K	Buy	+30,000	New	+$483K	﹤0.01%	7779
2025 Q4	–	Sell	-14,000	Closed	-$302K	–	12507
2025 Q3	$302K	Buy	14,000 +1,800	+15%	+$32.5K	﹤0.01%	8885
2025 Q2	$171K	Sell	12,200 -3,600	-23%	-$48.9K	﹤0.01%	8661
2025 Q1	$213K	Buy	+15,800	New	+$269K	﹤0.01%	8355
2024 Q4	–	Sell	-14,900	Closed	-$339K	–	10704
2024 Q3	$339K	Buy	+14,900	New	+$244K	﹤0.01%	7822
2023 Q2	–	Sell	-8,100	Closed	-$206K	–	9646
2023 Q1	$206K	Sell	8,100 -1,900	-19%	-$60.9K	﹤0.01%	7808
2022 Q4	$292K	Sell	10,000 -400	-4%	-$9.21K	﹤0.01%	7066
2022 Q3	$213K	Buy	+10,400	New	+$187K	﹤0.01%	8075

Other funds holding VRDN

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Jane Street's VRDN Position: Q2 2026 in Review

Jane Street sold out of Viridian Therapeutics (VRDN) in Q2 2026, closing a stake of 60,815 shares — an estimated $980K sold.

Jane Street first reported a position in VRDN in Q1 2018 and held it in 16 quarters. The position peaked at $8.7M in Q4 2025. 214 funds tracked by Wall St. Rank hold VRDN as of Q2 2026.

Jane Street reported no remaining Viridian Therapeutics position as of Q2 2026 after selling out during the quarter.
Jane Street sold 60,815 Viridian Therapeutics shares in Q2 2026, an estimated $980K.
Jane Street first reported a position in Viridian Therapeutics in Q1 2018 and held it in 16 quarters.
Jane Street's Viridian Therapeutics position peaked at $8.7M in Q4 2025.
214 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q2 2026.

Based on Jane Street's 13F filing for Q2 2026, filed 14 Aug 2026.